Document Detail

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
MedLine Citation:
PMID:  22741814     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: According to the definition of the Committee to Identify Neuroprotective Agents in Parkinson's Disease (CINAPS), "neuroprotection would be any intervention that favourably influences the disease process or underlying pathogenesis to produce enduring benefits for patients" [Meissner W, et al. Trends Pharmacol Sci 2004;25:249-253]. Preferably, neuroprotective agents should be used before or eventually during the prodromal phase of the diseases that could start decades before the appearance of symptoms. Although several symptomatic drugs are available, a disease-modifying agent is still elusive.
AREAS COVERED: The aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases.
EXPERT OPINION: Development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages, both conceptual and methodological. Novel solutions might be offered by evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multi-target approaches and network pharmacology.
Petra Dunkel; Christina Ll Chai; Beáta Sperlágh; Paul B Huleatt; Péter Mátyus
Related Documents :
11794774 - Risk-factor fusion for predicting multifactorial diseases.
17676214 - To evaluate the differences of risk factors in patients with lower extremity venous dis...
22223674 - Amyloid diseases of the heart: current and future therapies.
11157664 - Gene transfer as an approach to treating hemophilia.
23253124 - Triptolide with potential medicinal value for diseases of the central nervous system.
9129864 - Cognitive enhancement therapy for alzheimer's disease. the way forward.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-06-28
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  21     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-15     Completed Date:  2013-01-04     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1267-308     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alzheimer Disease / drug therapy,  physiopathology
Amyotrophic Lateral Sclerosis / drug therapy,  physiopathology
Drug Design*
Huntington Disease / drug therapy,  physiopathology
Neurodegenerative Diseases / drug therapy*,  physiopathology
Neuroprotective Agents / pharmacology,  therapeutic use*
Parkinson Disease / drug therapy,  physiopathology
Reg. No./Substance:
0/Neuroprotective Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Unintentional injury mortality in India, 2005: nationally representative mortality survey of 1.1 mil...
Next Document:  Reliability of Indicators of Decline in Abundance.